The FDA NDA acceptance is a high-impact catalyst with a clear timeline; traders should monitor for potential approval ahead of the December 2026 PDUFA date. While the OSA trial missed its primary endpoint, the strong BP reduction supports continued development in hypertension. The improved cash runway reduces near-term dilution risk.
How the stock moved after the report
BULLISH VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Mar 13 $26.19entry
- T+1 · 8mo ago −1.76%α −2.78% · $25.73
- T+5 · 8mo ago −8.09%α −5.98% · $24.07
- T+20 · 7mo ago +3.70%α +0.11% · $27.16
- T+60 · 5mo ago −14.09%α −25.70% · $22.50
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Mineralys Therapeutics reported its fourth quarter and full-year 2025 financial results, highlighted by a significant reduction in net loss due to lower R&D spending following the completion of its pivotal lorundrostat trials. The company also announced FDA acceptance of its NDA for lorundrostat in hypertension, with a PDUFA date of December 22, 2026, marking a major regulatory milestone. Cash reserves increased to $656.6 million, sufficient to fund operations into 2028.
Key Financial Metrics
Key Facts
- FDA accepted NDA for lorundrostat with PDUFA target date of December 22, 2026
- Cash, cash equivalents, and investments totaled $656.6 million as of December 31, 2025, up from $198.2 million in 2024
- Net loss decreased to $154.7 million in 2025 from $177.8 million in 2024
- R&D expenses declined to $132.0 million in 2025 from $168.6 million in 2024 due to completion of pivotal trials
- G&A expenses increased to $38.6 million in 2025 from $23.8 million in 2024 due to headcount growth and professional fees
- Lorundrostat failed to meet primary endpoint in Explore-OSA Phase 2 trial for obstructive sleep apnea, but showed significant blood pressure reduction
Financial Impact
Reduced annual R&D spend by $36.6 million and improved cash position by $458.4 million year-over-year; net loss reduced by $23.1 million despite higher G&A
Risk Factors
- Lorundrostat may not gain FDA approval despite NDA acceptance
- Failure in the OSA indication limits expansion potential
- Increased G&A spending could pressure margins if revenue is delayed
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3255107 |
Track record
35 reports on MLYS
3 of 6 bullish or bearish reports moved the stock their way by T+20. Best: +20.97% at T+20 after the Jun 11, 2026 report. 4 of 9 went positive at some point.
Filters
- Nov 8, 20268d ago Press Release Bullish 6/10 Entry $15.81 Now $14.53 −8.10% settles Dec 8
- Nov 4, 202612d ago 8-K Neutral 4/10 Entry $15.24 Now $14.53 −4.66% settles Dec 4
- Nov 3, 202613d ago Institutional Cluster Neutral 2/10 Entry $15.99 Now $14.53 −9.13% settles Dec 2
- Oct 29, 202618d ago 8-K Bullish 6/10 Entry $18.18 Now $14.53 −20.08% settles Nov 30
- Oct 28, 202619d ago Press Release Bullish 6/10 Entry $21.38 Now $14.53 −32.04% settles Nov 25
- Oct 20, 202627d ago 3 Neutral 2/10 Entry $21.10 Now $14.53 −31.14% settles Nov 18
- Oct 20, 202627d ago 3 Neutral 2/10 Entry $21.10 Now $14.53 −31.14% settles Nov 18
- Oct 19, 202628d ago 8-K Neutral 2/10 Entry $21.58 Now $14.53 −32.67% settles Nov 17
- Oct 13, 20264w ago 144 Neutral 3/10 Entry $20.76 to $16.16 Now $14.53 −30.01% ▼ −22.16% −20.89% vs SPY
- Sep 30, 20266w ago 144 Neutral 3/10 Entry $23.72 to $21.24 Now $14.53 −38.74% ▼ −10.46% −11.16% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers